Modelling the pathology and treatment of cardiac fibrosis in vascularised atrial and ventricular cardiac microtissues.
3D cardiac microtissues
cardiac fibrosis
cardiomyocytes
induced pluripotent stem cells
tissue engineering
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2023
2023
Historique:
received:
01
02
2023
accepted:
09
08
2023
medline:
20
9
2023
pubmed:
20
9
2023
entrez:
20
9
2023
Statut:
epublish
Résumé
Recent advances in human cardiac 3D approaches have yielded progressively more complex and physiologically relevant culture systems. However, their application in the study of complex pathological processes, such as inflammation and fibrosis, and their utility as models for drug development have been thus far limited. In this work, we report the development of chamber-specific, vascularised human induced pluripotent stem cell-derived cardiac microtissues, which allow for the multi-parametric assessment of cardiac fibrosis. We demonstrate the generation of a robust vascular system in the microtissues composed of endothelial cells, fibroblasts and atrial or ventricular cardiomyocytes that exhibit gene expression signatures, architectural, and electrophysiological resemblance to In conclusion, we present a novel methodology for the generation of chamber-specific cardiac microtissues that is highly scalable and allows for the multi-parametric assessment of cardiac remodelling and pharmacological screening.
Identifiants
pubmed: 37727305
doi: 10.3389/fcvm.2023.1156759
pmc: PMC10506403
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1156759Informations de copyright
© 2023 Reyat, di Maio, Grygielska, Pike, Kemble, Rodriguez-Romero, Simoglou Karali, Croft, Psaila, Simões, Rayes and Khan.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Elife. 2022 Jan 12;11:
pubmed: 35018887
Eur Heart J. 2013 Apr;34(15):1134-46
pubmed: 23103664
Nature. 2020 Nov;587(7835):555-566
pubmed: 33239795
Nat Protoc. 2013 Jan;8(1):162-75
pubmed: 23257984
Cell Stem Cell. 2021 Feb 4;28(2):230-240.e6
pubmed: 33176168
Nat Protoc. 2019 Nov;14(11):3082-3100
pubmed: 31554955
Cardiovasc Res. 2022 Dec 9;118(15):3016-3051
pubmed: 34999816
Lab Chip. 2021 Feb 9;21(3):473-488
pubmed: 33480945
Nat Rev Cardiol. 2020 Jun;17(6):341-359
pubmed: 32015528
Nat Commun. 2021 Aug 26;12(1):5142
pubmed: 34446706
Sci Rep. 2017 Aug 1;7(1):7005
pubmed: 28765558
Nat Commun. 2020 Sep 3;11(1):4283
pubmed: 32883967
Circ Res. 2023 Feb 17;132(4):483-497
pubmed: 36795846
J Mol Cell Cardiol. 2021 Aug;157:56-65
pubmed: 33895197
Cell. 2021 Jun 10;184(12):3299-3317.e22
pubmed: 34019794
JCI Insight. 2020 Aug 6;5(15):
pubmed: 32603312
J Heart Lung Transplant. 2016 Jan;35(1):137-145
pubmed: 26433566
Circ Res. 2022 Jun 10;130(12):1780-1802
pubmed: 35679369
JCI Insight. 2018 Jun 21;3(12):
pubmed: 29925689
Front Cardiovasc Med. 2018 Jul 26;5:101
pubmed: 30175102
Biotechnol Bioeng. 2018 Mar;115(3):630-644
pubmed: 29178315
Nat Biotechnol. 2021 Jun;39(6):737-746
pubmed: 33558697
Cell Stem Cell. 2020 Jun 4;26(6):862-879.e11
pubmed: 32459996
Int Heart J. 2017 Dec 12;58(6):957-961
pubmed: 29162778
Tissue Eng Part A. 2009 Jun;15(6):1211-22
pubmed: 19063661
PLoS One. 2018 May 23;13(5):e0198026
pubmed: 29791489
J Biol Eng. 2019 Feb 13;13:15
pubmed: 30809271
Nature. 2019 Jan;565(7740):505-510
pubmed: 30651639
EMBO Mol Med. 2015 Feb 19;7(4):394-410
pubmed: 25700171
Commun Biol. 2022 Apr 29;5(1):399
pubmed: 35488063
Front Physiol. 2018 Aug 23;9:1194
pubmed: 30190684
Cells. 2020 Jul 20;9(7):
pubmed: 32698471
Nat Commun. 2018 Aug 7;9(1):3140
pubmed: 30087351
Physiol Rev. 2005 Oct;85(4):1205-53
pubmed: 16183911
Nat Methods. 2014 Aug;11(8):855-60
pubmed: 24930130
JACC Basic Transl Sci. 2019 Apr 29;4(2):269-274
pubmed: 31061928
Biomaterials. 2019 Feb;192:537-550
pubmed: 30529872
Cell Mol Life Sci. 2017 Oct;74(20):3711-3739
pubmed: 28573431
Nature. 2021 Jul;595(7867):438-443
pubmed: 34163071
Sci Transl Med. 2017 May 17;9(390):
pubmed: 28515341
Toxicol Sci. 2016 Jul;152(1):99-112
pubmed: 27125969
Circulation. 2020 Aug 4;142(5):466-482
pubmed: 32403949
Nature. 2020 Dec;588(7838):466-472
pubmed: 32971526
EMBO Mol Med. 2020 Oct 7;12(10):e10865
pubmed: 32955172
Circ Res. 2021 Mar 19;128(6):775-801
pubmed: 33734815
Circ Res. 2020 Jul 3;127(2):207-224
pubmed: 32228120
Toxicol Sci. 2017 Feb;155(2):444-457
pubmed: 28069985
Proc Natl Acad Sci U S A. 2009 Sep 29;106(39):16568-73
pubmed: 19805339
Nat Biomed Eng. 2020 Apr;4(4):446-462
pubmed: 32284552
Cardiovasc Res. 2008 Jan;77(1):107-17
pubmed: 18006470
Development. 2017 Mar 15;144(6):1008-1017
pubmed: 28279973
Circ Res. 2021 Jul 9;129(2):326-341
pubmed: 34018815
Front Physiol. 2021 Sep 03;12:716721
pubmed: 34539441
Eur J Heart Fail. 2022 Oct;24(10):1778-1791
pubmed: 35867781
Mol Pharmacol. 2002 Jul;62(1):65-74
pubmed: 12065756
Circ Res. 2019 Sep 13;125(7):662-677
pubmed: 31409188
JCI Insight. 2021 Aug 9;6(15):
pubmed: 34369384
Biosensors (Basel). 2017 Jun 23;7(3):
pubmed: 28644395
Integr Pharm Res Pract. 2019 Feb 04;8:1-11
pubmed: 30788283
Cardiovasc Res. 2022 Dec 9;118(15):3085-3096
pubmed: 35709328
J Vis Exp. 2021 Sep 15;(175):
pubmed: 34605811
Biomolecules. 2020 Nov 22;10(11):
pubmed: 33266431
J Vis Exp. 2015 Mar 18;(97):
pubmed: 25867738
Nat Rev Cardiol. 2022 Jul;19(7):435-455
pubmed: 34983937
Front Mol Biosci. 2020 Feb 14;7:14
pubmed: 32118040
Cell Stem Cell. 2021 Dec 2;28(12):2137-2152.e6
pubmed: 34861147
Lancet. 2020 Oct 17;396(10258):1204-1222
pubmed: 33069326
J Cardiovasc Dev Dis. 2019 Sep 23;6(4):
pubmed: 31547577
J Am Coll Cardiol. 2020 Dec 22;76(25):2982-3021
pubmed: 33309175
Proc Natl Acad Sci U S A. 2012 Jul 3;109(27):E1848-57
pubmed: 22645348
Biomaterials. 2017 Oct;142:112-123
pubmed: 28732246